BioVersys Advances AlpE Combo Into Phase 2a for Severe Tuberculosis Meningitis

BioVersys AG (CH:BIOV) announced an update on their ongoing clinical study.

BioVersys AG (CH:BIOV) is preparing a Phase 2a trial titled “A Multicenter, Open-label, Randomized, Active-controlled, Phase 2a Study to Evaluate the Pharmacokinetics and Safety of Alpibectir/Ethionamide in Combination With the Standard Regimen in Patients With Tuberculosis Meningitis.” The study will test how well the new AlpE drug mix reaches the brain, how safe it is, and how it may help in a severe form of tuberculosis that still has high death rates.

The main treatment under review is AlpE, a fixed-dose mix of alpibectir and ethionamide added to the current HRZE backbone used for tuberculosis. The goal is to boost killing of the bacteria in the brain and to keep side effects manageable, while also checking how AlpE interacts with dolutegravir in patients who also live with HIV.

The study is an interventional Phase 2 trial with patients randomly placed into one of four groups, each following a different dosing plan. It uses an open-label, parallel group design with no blinding, and the core aim is treatment focused, looking at drug levels in blood and spinal fluid plus safety over the early weeks of therapy.

Key dates include first submission on 16 January 2026, showing recent regulatory engagement and planning. The last update on 28 February 2026 confirms that the protocol is current and still marked as “not yet recruiting,” so patient dosing and early data are still ahead.

For investors, this update signals that BioVersys is advancing a high-risk, high-need asset in a niche area of infectious disease, which can support sentiment around its pipeline story but will not drive near-term cash flows. Success could position BioVersys competitively against larger anti-infective players and specialty TB developers, yet the early stage and complex patients mean binary event risk and long timelines remain high.

The study is ongoing at the planning stage, with the latest details available on the ClinicalTrials portal.

To learn more about CH:BIOV’s potential, visit the BioVersys AG drug pipeline page.